<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04716335</url>
  </required_header>
  <id_info>
    <org_study_id>2018-01385</org_study_id>
    <nct_id>NCT04716335</nct_id>
  </id_info>
  <brief_title>Neurodynamics of Prosocial Emotional Processing Following Serotonergic Stimulation With N,N-Dimethyltryptamine (DMT) and Harmine in Healthy Subjects</brief_title>
  <official_title>Neurodynamics of Prosocial Emotional Processing Following Serotonergic Stimulation With N,N-Dimethyltryptamine (DMT) and Harmine in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Psychiatric University Hospital, Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Basel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Psychiatric University Hospital, Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the project is to assess brain network dynamics, self-referential information&#xD;
      processing and prosociality and learning following the modulation of the serotonin-system by&#xD;
      serotonergic-psychoactive compounds.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Actual">July 19, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Behavioral Outcome Measures (Social Value Orientation - SVO, Charity Donation Frank Task)</measure>
    <time_frame>Acute drug effects (240 minutes - Charity Donation Frank Task, 300 minutes - SVO)</time_frame>
    <description>Social Cognition</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Behavioral Outcome Measures (Visuall Oddball, Karaoke Task)</measure>
    <time_frame>Acute drug effects (60 min - Visuall Oddball, 150 min - Karaoke Task)</time_frame>
    <description>Self-referential Processing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Pharmacological-EEG (Lagged Phase Synchronicity)</measure>
    <time_frame>Baseline, Acute drug effects (30 minutes , 135 minutes, 195 minutes, 285 minutes)</time_frame>
    <description>Functional brain connectivity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Pharmacological-EEG (Resting State)</measure>
    <time_frame>Baseline, Acute drug effects (30 minutes , 135 minutes, 195 minutes, 285 minutes)</time_frame>
    <description>Spectral Density</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Pharmacological-EEG</measure>
    <time_frame>Acute drug effects (60 minutes, 240 minutes)</time_frame>
    <description>Event-Related Potentials (ERP)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in biomarkers</measure>
    <time_frame>Baseline, Acute drug effects (0 minutes, 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes, 210 minutes, 240 minutes, 270 minutes, 300 minutes)</time_frame>
    <description>Tryptophan catabolites (TRYCAT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in biomarkers</measure>
    <time_frame>Baseline, Acute drug effects (30 minutes, 90 minutes, 150 minutes, 300 minutes)</time_frame>
    <description>Brain-derived Neurotrophic Factor (BDNF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in biomarkers</measure>
    <time_frame>Baseline, Acute drug effects (0 minutes, 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes, 210 minutes, 240 minutes, 270 minutes, 300 minutes)</time_frame>
    <description>Hypothalamic-Pituitary-Adrenal Axis (HPA-A)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in biomarkers</measure>
    <time_frame>Baseline, Acute drug effects (0 minutes, 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes, 210 minutes, 240 minutes, 270 minutes, 300 minutes)</time_frame>
    <description>API (DMT, Harmine)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in biomarkers</measure>
    <time_frame>Baseline, Acute drug effects (30 minutes, 90 minutes, 150 minutes, 300 minutes)</time_frame>
    <description>Neuroinflammation - Interleukines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in biomarkers</measure>
    <time_frame>Baseline, Acute drug effects (30 minutes, 90 minutes, 150 minutes, 300 minutes)</time_frame>
    <description>Oxidative Stress Markers (Nitric Oxide Synthase)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychometry</measure>
    <time_frame>Baseline, Acute, 1 day after, 1 week after, 1 month after and 4 month after intervention</time_frame>
    <description>Cognitive Flexibility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychometry</measure>
    <time_frame>Baseline, Acute, 1 day after, 1 week after, 1 month after and 4 month after intervention</time_frame>
    <description>MINDSENS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychometry</measure>
    <time_frame>Baseline, Acute, 1 day after, 1 week after, 1 month after and 4 month after intervention</time_frame>
    <description>PANAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychometry</measure>
    <time_frame>Baseline, Acute, 1 day after, 1 week after, 1 month after and 4 month after intervention</time_frame>
    <description>CFI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychometry</measure>
    <time_frame>Baseline, Acute, 1 day after, 1 week after, 1 month after and 4 month after intervention</time_frame>
    <description>SRQ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychometry</measure>
    <time_frame>Baseline, Acute, 1 day after, 1 week after, 1 month after and 4 month after intervention</time_frame>
    <description>MBQ</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Emotions</condition>
  <condition>Mood</condition>
  <condition>Cognitive Function 1, Social</condition>
  <condition>Empathy</condition>
  <arm_group>
    <arm_group_label>Harmine + DMT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Harmine + Placebo(DMT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo(Harmin &amp; Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DMT</intervention_name>
    <description>DMT</description>
    <arm_group_label>Harmine + DMT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Harmine</intervention_name>
    <description>Harmine</description>
    <arm_group_label>Harmine + DMT</arm_group_label>
    <arm_group_label>Harmine + Placebo(DMT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Harmine)</intervention_name>
    <description>Placebo for Harmine</description>
    <arm_group_label>Placebo(Harmin &amp; Placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (DMT)</intervention_name>
    <description>Placebo for DMT</description>
    <arm_group_label>Harmine + Placebo(DMT)</arm_group_label>
    <arm_group_label>Placebo(Harmin &amp; Placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and capable to give informed consent for the participation in the study after&#xD;
             it has been thoroughly explained&#xD;
&#xD;
          -  Little or no previous experiences with psychedelic substances&#xD;
&#xD;
          -  Body mass index (BMI) between 18.5 and 25&#xD;
&#xD;
          -  Willing to refrain from drinking caffeine 3 days and alcohol the day before testing&#xD;
             session, from drinking alcohol and caffeinated drinks at the testing days and from&#xD;
             consuming psychoactive substances or other medications for 2 weeks before testing days&#xD;
             and for the duration of the study&#xD;
&#xD;
          -  Able and willing to comply with all study requirements&#xD;
&#xD;
          -  Informed consent form was signed&#xD;
&#xD;
          -  Good knowledge of the German language&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous significant adverse response to a hallucinogenic drug&#xD;
&#xD;
          -  Participation in another study where pharmaceutical compounds will be given&#xD;
&#xD;
          -  Self or first-degree relatives with present or antecedent psychiatric disorders&#xD;
&#xD;
          -  History of head trauma or fainting&#xD;
&#xD;
          -  Recent cardiac or brain surgery&#xD;
&#xD;
          -  Current use of medication or psychotropic substances (including nicotine addiction)&#xD;
&#xD;
          -  Presence of major internal or neurological disorders (including sepsis,&#xD;
             pheochromocytoma, thyrotoxicosis, drug-induced fibrosis, familiar or basilar artery&#xD;
             migraine)&#xD;
&#xD;
          -  Cardiovascular disease (hypertonia, coronary artery disease, heart insufficiency,&#xD;
             myocardial infarction, coronary spastic angina)&#xD;
&#xD;
          -  Peripheral vascular disease (thromboangiitis obliterans, luetic arteritis, severe&#xD;
             arteriosclerosis, thrombophlebitis, Raynaud's disease)&#xD;
&#xD;
          -  Liver or renal disease&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Psychiatric University Hospital</name>
      <address>
        <city>Zürich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 23, 2020</study_first_submitted>
  <study_first_submitted_qc>January 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>November 7, 2021</last_update_submitted>
  <last_update_submitted_qc>November 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Psychiatric University Hospital, Zurich</investigator_affiliation>
    <investigator_full_name>Milan Scheidegger</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Harmine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

